A continual reassessment method without undue risk of toxicity
From MaRDI portal
Publication:6171847
DOI10.1080/03610918.2021.1877306OpenAlexW3128946471MaRDI QIDQ6171847
Xikui Wang, Saman Muthukumarana, Weijia Zhang, Po Yang
Publication date: 18 July 2023
Published in: Communications in Statistics - Simulation and Computation (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1080/03610918.2021.1877306
Bayesian methodmaximum tolerated dosecontinual reassessment methodtoxicitydose findingphase i clinical trials
Cites Work
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- The treatment versus experimentation dilemma in dose finding studies
- Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
- Continual reassessment and related dose-finding designs
- Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
- Approximate dynamic programming and its applications to the design of Phase I cancer trials
- Optimal sequential designs in phase I studies
- Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials
- Adaptive clinical trial designs for phase I cancer studies
- Design and Analysis of Phase I Clinical Trials
- Semiparametric Dose Finding Methods
- A new design of the continual reassessment method
- Simple benchmark for complex dose finding studies
- Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials
This page was built for publication: A continual reassessment method without undue risk of toxicity